Molecular classification has demonstrated a high prognostic value in high-risk endometrial cancer, with significantly improved recurrence-free survival with adjuvant chemoradiotherapy for tumors with abnormal p53 (p53abn), regardless of the histological type [39]. The gene discussed is TP53; the disease is endometrial cancer.